Leukemia Research and Treatment / 2012 / Article / Tab 2

Research Article

Identification of a Novel P190-Derived Breakpoint Peptide Suitable for Peptide Vaccine Therapeutic Approach in Ph+ Acute Lymphoblastic Leukemia Patients

Table 2

p190-13 peptide-specific CD4+ T cell proliferation obtained in 5 healthy donor (HD) and 6 Ph+ ALL patients (HD: healthy donor; SI: stimulation index; HR: hematologic remission).

Age, sexDisease stageCurrent treatmentp190-13 CD4+ T cell SI

HD 158 M2.0
HD 243 F2.5
HD 355 M2.3
HD 434 M2.7
HD 552 F2.3
Ph+ ALL 173 MHRdasatinib1.0
Ph+ ALL 269 FHRdasatinib1.0
Ph+ ALL 357 FHRdasatinib2.2
Ph+ ALL 443 MHRimatinib2.0
Ph+ ALL 564 FHRimatinib2.2
Ph+ ALL 672 FHRimatinib2.1

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.